2/24/2010

A late-stage trial showed that Genentech's Avastin did not prolong overall survival of patients with inoperable, advanced or metastatic stomach cancer when administered in combination with ciaplatin and Roche Holding's Xeloda. Avastin also is being tested for other forms of cancer, including ovarian.

Related Summaries